Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
09:50pm, Wednesday, 10'th Apr 2024
MILWAUKEE , April 10, 2024 /PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex. Click he
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
08:16pm, Wednesday, 10'th Apr 2024
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
08:08pm, Wednesday, 10'th Apr 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $6
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
05:15pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
04:45pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln
04:20pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
10:26am, Tuesday, 09'th Apr 2024
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
04:30pm, Wednesday, 20'th Mar 2024
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
08:26pm, Monday, 18'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This compares to loss of $0.41 per share a y
Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript
07:24pm, Monday, 18'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
09:40am, Thursday, 14'th Mar 2024
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Monday, 11'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
04:30pm, Thursday, 07'th Mar 2024
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade)
05:10pm, Friday, 22'nd Dec 2023
Alpine Immune Sciences, Inc. stock has increased by 176% since early coverage, driven by positive data from the basket study RUBY-3. Low-dose povetacicept showed meaningful improvements in disease bio
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 18'th Dec 2023
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
